Imaging Biomarkers in Preclinical and Symptomatic AD

Part of paid clinical trials in St Louis, Missouri.

Sponsor
Tammie L. S. Benzinger, MD, PhD
Study ID
NCT04134923
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • [11C] Pittsburgh Compound-B (PIB) — DRUG
    Participants will receive a single intravenous bolus injection of 6.0 - 20.0 mCi (222-740 MBq) of the investigational radiotracer \[11C\] PIB. Participants will then undergo a \[11C\] PIB PET/CT scan conducted in the Center for Clinical Imaging Research (CCIR) facility.

Study Details

The purpose of this research study is to evaluate adult children of parents with and without Alzheimer's disease which represent an ideal population for investigating the biological changes that precede the clinical onset of AD. The investigators will be imaging the brain to detect the presence of amyloid deposits (plaques in the brain). Amyloid is a protein that may be related to dementia of Alzheimer's disease (DAT).

Key Dates

Start date
Jun 8, 2021
Status verified
Aug 2025
Primary completion
Oct 31, 2026
Completion
Oct 31, 2029

Study Design

Enrollment
375 participants (estimated)

Arms

  • Arm: [11C] Pittsburgh Compound-B (PIB)
    Using \[11C\] Pittsburgh Compound-B (PIB) to look for biomarkers in preclinical and symptomatic AD.

Primary Outcome Measure

develop an integrated timeline for the imaging changes which occur during the transition from asymptomatic to symptomatic AD [ Time Frame: 5 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Washington University School of MedicineSt LouisMissouri63110
Lauren Ash
[email protected]
314-273-6175

Find similar trials in St Louis, MO

By condition
Alzheimer's disease
By specialty
NeurologyDementia careBrain disordersGeriatrics
By research site
Washington University School of Medicine· St Louis, MO

Related Studies